117 results about "Pharmacologic therapy" patented technology

Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

A method for treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional agents is described herein.

The invention discloses an STING agonist polypeptide conjugate as well as a composition and application thereof, and belongs to the field of medicinal chemistry, an STING agonist and a straight-chain peptide or a cyclic peptide are directly connected or connected through a linking group, the formed conjugate can target a tumor microenvironment, and the STING agonist is controllably released in specific time and space, so that the tumor microenvironment is inhibited, and the tumor microenvironment is inhibited. Therefore, the drug enrichment amount of the tumor site is increased, the drug treatment efficiency and bioavailability are improved, the toxic and side effects are reduced, and the purposes of effect enhancement and toxicity reduction are achieved. According to the STING agonist polypeptide conjugate, the targeting property of STING agonist drugs on tumor tissues is improved, the toxic and side effects on normal tissues are reduced, the STING agonist polypeptide conjugate is a brand-new immune agonist type coupling drug, and a new scheme is provided for tumor immunotherapy research.

The invention provides a traditional Chinese medicine composition for treating Alzheimer's disease. Relates to the technical field of traditional Chinese medicine preparations, the weight part ratio of rhizoma polygonati to radix astragali is 1: (1-1.2), a progressive increase type structure is adopted among rhizoma polygonati, radix astragali and poria cocos, and the progressive increase type structure meets the condition that radix astragali is larger than or equal to poria cocos and is larger than or equal to rhizoma polygonati; the sum of the parts by weight of the basic support components accounts for 40-55% of the total parts by weight of the traditional Chinese medicine composition. According to the traditional Chinese medicine composition for treating the Alzheimer's disease, the basic support component, the collateral dredging and regulating component and the active intervention component are reasonably distributed through a definite fixed matching structure, and it is ensured that all the components cooperate with one another and act more stably. By setting an incremental structure and a bidirectional locking proportional structure between the medicinal materials, the composition fluctuation is reduced, so that the composition of each batch has higher consistency, and the stability of the treatment effect of the medicine is enhanced.

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and / or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.

The invention belongs to the field of biological medicine, and particularly relates to a YBX3 gene, a YBX3 gene inhibitor and application of the YBX3 gene inhibitor. The invention discloses application of the YBX3 gene as a biomarker in preparation of a product for detecting cardiac fibrosis. The nucleotide sequence of the YBX3 gene is as shown in SEQ ID NO. 1. The invention discloses application of a YBX3 gene inhibitor in preparation of drugs for preventing and / or treating heart diseases. The YBX3 gene inhibitor is shRNA (short hairpin ribonucleic acid) and has a nucleotide sequence as shown in SEQ ID NO. 3. When myocardial infarction occurs, mRNA and protein level expression activity of the YBX3 gene is remarkably improved and is related to fibroblast activation, and the silent YBX3 gene can remarkably inhibit fibroblast activation. The existing myocardial infarction injury medicine has a limited treatment effect, so that the YBX3 can improve the clinical prognosis of myocardial infarction injury by regulating and controlling the activation of cell fibrosis.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention relates to medicine and can be used for overcoming stuttering by developing the rhythmic component of speech. Exercises are performed on a step-by-step basis. In a first step, exercises are performed for the muscles of the respiratory, phonatory and articulatory systems. In a second step, an individual non-speech rhythm is cultivated. In a third step, a sense of rhythm is developed. In a fourth step, a poetic speech rhythm is cultivated. In a fifth step, a prosaic speech rhythm is cultivated. In a sixth step, narrative and interrogative intonations are cultivated. In a seventh step, rhythmic processes are trained to become automatic in independent speech. The method makes it possible to overcome psychogenic and neurogenic stuttering, without the use of medication or the risk of relapse, and is suitable for all age groups.

The application provides a method for constructing an animal model of systemic lupus erythematosus, and the animal model of systemic lupus erythematosus shows high autoantibody, low complement, high inflammatory factor and severe kidney damage. The animal model of systemic lupus erythematosus provided by the application has a clear cause, can cause abnormalities of innate immunity and acquired immunity systems, and has a short experimental cycle, thereby providing a new animal model for drug candidate screening, drug treatment effect evaluation and pathogenesis research of systemic lupus erythematosus.

This invention relates to the field of bioinformatics, and particularly to an artificial intelligence-based drug relocation method, apparatus, device, and storage medium. The AI-based drug relocation method of this invention first constructs a heterogeneous network, and then builds a relocation model including a multi-relational heterogeneous graph encoder, a multi-head attention mechanism module, and an interactive decoder. Based on the heterogeneous network, it predicts the treatment score of a drug for a disease, achieving better test metrics compared to other methods. Furthermore, this invention interprets the prediction results, identifying key functional nodes and explaining the pharmacological mechanism of drug treatment for diseases.

Relates to an anti-IL4R antibody. Specifically, the invention provides an antibody capable of specifically binding to IL4R or an antigen binding fragment thereof, and the antibody or the antigen binding fragment thereof can specifically bind to IL4R with high affinity and can be used as a drug for treating IL4R-related diseases.

The invention relates to the technical field of biological medicine, in particular to a multifunctional ternary complex based on cyclodextrin and a preparation method thereof. The invention provides a multifunctional curcumin / methotrexate ternary complex based on beta-cyclodextrin. The ternary complex can realize synergistic delivery and controlled-release release of natural polyphenol and synthetic drugs in a medication mode of'one dose with multiple effects'. Meanwhile, the problems that a traditional medicine is poor in water solubility and low in bioavailability, the treatment effect of a single medicine is limited, and an existing nano delivery system is complex in structure, tedious in preparation and the like are solved, and the technical requirements of modern medicine preparations are met.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The present invention relates to a computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus. The method is based on glucose data from said individual that are received at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said individual, and / or at least three matched pre-prandial glucose measurement values and postprandial glucose measurement values at the same meal from said individual. Further contemplated by the present invention is a device for aiding in the guidance of drug diabetes therapy of an individual suffering from diabetes, said device comprising a processing unit, and a computer program including computer-executable instructions, wherein said instructions, when executed by the processing unit, causes the processing unit to perform the computer-implemented method of the present invention.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.

The present disclosure provides methods of treating and / or preventing sexual desire disorders associated with treatment of patients with GLP-1 agonists and / or related compounds. In particular, the methods involve administration of flibanserin or a pharmaceutically acceptable salt, solvate, or hydrate thereof. The disclosure also provides related pharmaceutical compositions and kits containing one or more compositions including flibanserin and one or more GLP-1 agonists and / or related compounds.

This specification describes methods for treating cancer using small molecule ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitors and additional agents.

The invention provides a method for evaluating the efficacy of treating climacteric hectic fever, which comprises the following steps: collecting literature data of climacteric hectic fever according to a predetermined standard, constructing a data set, and evaluating the quality of the data set; constructing a pharmacodynamic model based on a quality evaluation result and a predetermined curative effect index in the data set, and evaluating the constructed pharmacodynamic model; and performing quantitative analysis processing on time effect distribution and covariable influence factors of drug treatment based on the evaluated pharmacodynamic model so as to simulate and predict result data of drug efficacy parameters and covariable influence degrees of drugs to evaluate time-effect characteristics of drug treatment. The evaluation method can assist in determining the optimal clinical medication treatment strategy of the medicine, and can also provide a diachronic standard curative effect scale reference for the development of a new medicine for treating female climacteric hectic fever.

In part of this specification, a pharmaceutical composition containing an antiviral prodrug and a method of using the drug in the treatment of a viral infection are disclosed.

This invention belongs to the field of biomedical nanomaterials and radiation damage drugs, specifically relating to a magnesium-ethylene glycol tetraacetic acid (EGTA) nanomedicine, its preparation method, and its applications. This study proposes using magnesium-EGTA nanomedicine to treat radiation dermatitis. EGTA's chelating ability for calcium ions is significantly higher than that of magnesium ions and other metal ions. Its unique ion selectivity provides an important theoretical basis and application potential for targeting and inhibiting mitochondrial calcium overload in the pathological process of radiation dermatitis. Magnesium ions are cofactors of many enzymes and have anti-inflammatory, collagen synthesis-promoting, and angiogenesis-enhancing effects. This study constructs a Mg-EGTA-based nanomedicine system, utilizing EGTA's stronger chelating ability for calcium ions, thereby achieving targeted regulation of mitochondrial calcium homeostasis through a calcium-magnesium ion intelligent replacement mechanism in response to calcium overload, providing new ideas and methods for the prevention and treatment of radiation dermatitis.

This application discloses a tumor-targeting nanoparticle, its preparation method, and its application, belonging to the field of tumor drug technology. The tumor-targeting nanoparticle includes a drug and a delivery carrier loading the drug, wherein the drug is atorvaquinone. The delivery carrier is prepared by coupling an intermediate product with Sulfo-SMCC-BSA. The intermediate product is obtained by reducing a thiol-modified nucleic acid aptamer, wherein the nucleic acid aptamer is EGFR aptamer. This application utilizes a EGFR-targeting nucleic acid aptamer coupled with bovine serum albumin (BSA) to encapsulate atorvaquinone, successfully constructing a novel atorvaquinone nanomedicine. This improves the targeting ability of atorvaquinone and increases its water solubility, providing a new approach for the treatment of esophageal cancer with atorvaquinone nanomedicines.

It is well understood in the medical industry that medical disorders can manifest as serious problems for the affected subjects, their families, and society. Today, psychiatrists, neurologists and other physicians treat these disorders with a variety of medications, many of which have significant negative side effects. The teachings provided herein are directed to a novel system and methods for treating certain neurological, psychological, psychiatric and medical disorders by delivering a “magnetic stimulation” to a subject's neural and perineural system using either a static or electromagnetic field to generate a modulated variable power multi-spectral magnetic stimulation on three axis; the modulated stimulation using methods that have predictable, controlled, modifiable, and repeatable characteristics.

According to the treatment method, a cancer patient with negative P53 gene mutation and positive KRAS gene mutation is treated by using a drug containing an AKR1C3 enzyme activated or hypoxia activated anti-cancer prodrug compound or salt, ester, solvate and isotope isomer of the AKR1C3 enzyme activated or hypoxia activated anti-cancer prodrug compound singly or in combination with other drugs; treating a cancer patient with negative P53 gene mutation and positive BRCA gene mutation; treating cancer patients with positive KRAS gene mutation and positive BRCA gene mutation; or cancer patients meeting the three conditions of negative P53 gene mutation, positive KRAS gene mutation and positive BRCA gene mutation at the same time can be treated.

Disclosed is a method for treatment of a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug. Specifically, the method includes the following steps: treating the tumor by using the recombinant oncolytic virus in combination with the small-molecule anticancer drug, wherein the small-molecule anticancer drug includes a small-molecule anticancer drug targeting ALK, a small-molecule anticancer drug targeting BTK, a small-molecule anticancer drug targeting EGFR, a small-molecule anticancer drug targeting FGFR, a small-molecule anticancer drug targeting HER2, a small-molecule anticancer drug targeting Parp, a small-molecule anticancer drug targeting PI3K, a small-molecule anticancer drug targeting VEGFR, a small-molecule anticancer drug targeting CDK4 / 6, and a small-molecule anticancer drug targeting KRAS; and the recombinant oncolytic virus comprises an M protein, a G protein, an N protein, a P protein, and an L protein after site-directed mutagenesis.

The invention relates to the technical field of application, and discloses a far infrared magnet therapy medicine application which comprises a base material layer, a bonding layer is fixedly connected to the upper end of the base material layer, a supporting layer is arranged at the upper end of the bonding layer, a protective layer is arranged at the upper end of the supporting layer, and an antibacterial layer is fixedly connected to the lower end of the base material layer. A microcapsule medicine area, an annular magnet and a far infrared therapy core are embedded in the middle of the interior of the adhesive layer, the upper end face of the microcapsule medicine area is of a circular structure, the annular magnet is connected to the outer side of the microcapsule medicine area in a sleeving mode, the far infrared therapy core is connected to the outer side of the annular magnet in a sleeving mode, and the microcapsule medicine area, the annular magnet and the far infrared therapy core are coaxially arranged. According to the far infrared magnet therapy medicine application, effective medicine treatment can be provided, the treatment effect can be enhanced through the synergistic effect of magnet therapy and far infrared therapy, meanwhile, long-acting release of medicine is ensured through a large number of microcapsule bodies arranged in the microcapsule medicine area, the treatment time is prolonged, and the treatment effect is improved.

Hyperthyroid diarrhea refers to hyperthyroid diarrhea, which is mostly intractable diarrhea, due to excessive thyroid hormone causing increased intestinal peristalsis excitability and diarrhea when the thyroid function is increased, which is caused by endocrine metabolic disorder leading to gastrointestinal function disorder. The present application studies and observes the treatment effect of kaempferol coupling derivative JC-1 on diarrhea of hyperthyroid model mice, and provides a new drug treatment option for diarrhea type colon dysfunction.

The invention relates to a silibinin derivative as well as a preparation method and application thereof, and belongs to the technical field of chemistry. The invention relates to a silibinin derivative, which is 6-sulfonated silibinin sodium sulfonate, the chemical name of the silibinin derivative is 2, 3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-hydroxymethyl-6-(3, 5, 7-trihydroxy-4-oxo benzopyran-2-yl) benzodioxane-6-sodium sulfonate, the molecular formula of the silibinin derivative is C25H21NaO13S, and the molecular weight of the silibinin derivative is 584.49. Sulfonic acid groups with hydrophilicity are introduced into different parts of the silibinin to prepare different types of silibinin sodium sulfonate, so that the solubility of the silibinin sodium sulfonate in water is enhanced, the pharmacokinetic characteristics of the silibinin are improved from the pharmacokinetic level, the affinity and biological activity of the silibinin to organisms are improved, and the application prospect of the silibinin sodium sulfonate is widened. The compound is further prepared into an injection for clinical treatment, and has important clinical drug treatment value.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating systemic lupus erythematosus. The structure of the CD177 targeting membrane modified lipidosome is divided into three layers, and comprises a lipidosome loaded with a PADI4 inhibitor, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the lipidosome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. In an imiquimod (IMQ)-induced lupus model, the medicine treatment shows strong disease remission capability: 1) improving the whole body phenotype: obviously reducing the swollen spleen and lymph node of lupus mice; 2) repairing kidney functions: significantly relieving glomerulonephritis, and reducing inflammatory cell infiltration and IgG and complement C3 deposition in glomerulus, and 3) significantly reducing the level of proinflammatory cytokines in serum and the titer of a lupus marker anti-dsDNA antibody.